31 May 2022
Cambridge Cognition partners on ambitious project for digital measurement of Alzheimer’s disease and related dementia symptoms
Cambridge Cognition is pleased to announce that they have joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measure Development project. As a partner of this innovative, collaborative effort, Cambridge Cognition will work to harness the potential of digital medicine to advance therapies for ADRD.
ADRD is one of the biggest global health challenges, affecting an estimated 47 million people around the world. There is a desperate need to better understand the causes, early signs, symptoms and progression of the conditions to enable earlier diagnosis and to provide better care for patients.
Digital tools such as wearable sensors and electronic cognitive assessments are increasingly being used in clinical studies to track patients’ symptoms in real-world settings and to understand the impact of a condition on their daily lives. While these digital measures hold a great deal of potential to better understand the signs and symptoms of ADRD, they have not been widely adopted in clinical studies. One reason for this is that there is a lack of standard digital measures that can determine whether potential treatments are working.
The DiMe project brings together 24 leading organisations with expertise in digital medicine, drug development, dementia research and patient care, with the aim of developing a core set of digital measures for ADRD. This collaborative work will bring consensus, consistency and effectiveness to the way digital measures are used to monitor the impact of the conditions. Ultimately, DiMe and its partners aim to issue resources that the field can use to improve the lives of people affected by ADRD through better clinical care and by driving the search for new treatments.
For more information on the initiative, please see here.